Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Preclinical findings highlight bacterial groups that influence the risk for graft-versus-host-disease in blood cancer transplant patients.
Ruxolitinib might have contributed to a functional cure after a stem cell transplant without a rare mutation.
A three-drug regimen helps protect against GVHD after stem cell transplant for those with leukemia, lymphoma and similar cancers.
Meet Cameron Ford. At 12, she was diagnosed with multiple myeloma. She’s now 27 and cancer-free. Here, she shares advice for survivors.
Tests prevented relapse and limited graft-vs.-host disease (GVHD) in laboratory models of leukemia and multiple myeloma.
Hutch scientists explore how our immune system can team with our microbiome to fight cancer and other life-threatening diseases.
Removing naive T cells before a stem cell transplant in certain cancer patients may prevent chronic graft-versus-host disease.
More than two-thirds of patients with blood cancer who experienced septic shock died within 28 days, finds MD Anderson Cancer Center.
Microbiome triggers top killer after bone marrow transplant — and there’s a potential way to stop it
‘To have your life-threatening cancer cured, and then to die of not being able to breathe? It’s devastating.’
ASH 2018 conference highlights precision medicine, machine learning and gut microbiome.
The Microbiome Research Initiative symposium highlighted research on how the gut interacts with the immune system and its effects on cancer.
Trials for head and neck cancer, pancreatic cancer, acute myeloid leukemia and myelodysplastic syndrome, among others, will receive funding.
“When your doctor says the No. 1 pediatric stem cell transplant hospital in the world is 90 minutes from your house, you don’t question it...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.